CBU
MRVI icon

CIBC Bancorp USA’s Maravai LifeSciences MRVI Stock Holding History

CIBC Bancorp USA’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$33.4K Buy
+11,651
New +$29.8K ﹤0.01% 1439

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

CIBC Bancorp USA's MRVI Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Maravai LifeSciences (MRVI) in Q3 2025: 11,651 shares worth $33.4K. The stake represents ﹤0.01% of the portfolio and ranks #1439 among its holdings.

160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

  • CIBC Bancorp USA held 11,651 shares of Maravai LifeSciences worth $33.4K as of Q3 2025.
  • Maravai LifeSciences was a new CIBC Bancorp USA position in Q3 2025.
  • Maravai LifeSciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1439 holding.
  • 160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.